ESSENTIAL THROMBOCYTHEMIA

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…

This early-phase study tests an experimental drug, JNJ-88549968, designed to help the immune system attack cancer cells with a specific genetic change (CALR mutation). About 220 adults with essential thrombocythemia or myelofibrosis will receive the drug to find a safe dose and c…

This study tests whether adding iadademstat to the standard drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 62 adults whose disease has progressed to a more aggressive phase will be ra…

This study tests a new drug, bomedemstat, against the standard treatment hydroxyurea for people with essential thrombocythemia (ET) who have not yet received treatment to lower their blood cell counts. The goal is to see if bomedemstat is better at safely reducing platelet counts…

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia, a condition where the body makes too many platelets. Participants must have tried hydroxyurea without success or had side effects. The goal is to see if…

This study tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia (a rare blood disorder causing too many platelets) whose disease did not respond to or who could not tolerate the standard drug hydroxyurea. Participants receive injections for up to 9…

This study compares two newer blood thinners (apixaban and rivaroxaban) against daily low-dose aspirin to prevent dangerous blood clots in people with JAK2-positive myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. About 1,300 high-risk adults (over 60 or wit…

This study tests whether the drug ruxolitinib can reduce symptoms like fatigue, itching, and night sweats in people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV) who have significant symptom burden. About 60 adults will take ruxolitinib and be monitored f…

This study tests N-acetylcysteine (N-AC), a supplement, in 27 adults with certain blood cancers (myeloproliferative neoplasms). The goal is to find the best dose that reduces symptoms like fatigue and pain while being safe. Participants continue their usual treatments during the …

This study is testing whether a curcumin supplement (the active ingredient in turmeric) can lower inflammation and improve symptoms in people with certain blood disorders, including low-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). About 30 adults wi…

This study is looking at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease or predict its course. About 70 participants will …

This study looks at whether measuring changes in a gene called CALR over time can help doctors predict when certain blood cancers (myeloproliferative neoplasms) are getting worse. Researchers will follow 260 adults diagnosed between 2006 and 2020, using stored blood samples and m…